natgillin/translations-raw huggingface dataset:
4. 8 og 5. 1).
In antiretroviral treatment experienced patients, the demonstration of efficacy is based on a study comparing REYATAZ 300 mg once daily in combination with ritonavir 100 mg once daily with lopinavir/ ritonavir, each regimen in combination with tenofovir (see sections 4.8 and 5.1).
På baggrund af eksisterende virologiske og kliniske data forventes der ikke antiviralt udbytte hos patienter med stammer, der er resistente over for flere proteasehæmmere (≥4 PI - mutationer).
Based on available virological and clinical data, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).
5. 1).
The choice of REYATAZ in treatment experienced patients should be based on individual viral resistance testing and the patient’ s treatment history (see section 5.1).
Behandling bør indledes af en læge med erfaring med behandling af HIV- infektion.
Therapy should be initiated by a physician experienced in the management of HIV infection.
Anbefalet dosis REYATAZ er 300 mg én gang dagligt sammen med 100 mg ritonavir én gang dagligt og sammen med et måltid.
Adults: the recommended dose of REYATAZ is 300 mg once daily taken with ritonavir 100 mg once daily and with food.
4. 5 og 5. 1).
Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1).
Hvis kombinationen af REYATAZ og ritonavir gives samtidig med didanosin, anbefales det at tage didanosin 2 timer efter REYATAZ med ritonavir.
If REYATAZ with ritonavir is co-administered with didanosine, it is recommended that didanosine be taken 2 hours after REYATAZ with ritonavir.
4. 5).
REYATAZ with ritonavir must be taken with food (see section 4.5).
5. 2).
Infants, toddlers, children, and adolescents: the safety and efficacy of REYATAZ in paediatric patients has not been established (see section 5.2).
5. 2).
Patients with renal impairment: no dosage adjustment is needed (see section 5.2).
4. 3, 4. 4 og 5. 2).
REYATAZ should not be used in patients with moderate to severe hepatic impairment (see sections 4.3, 4.4, and 5.2).
Til oral anvendelse.
2 Method of administration: for oral administration.
REYATAZ fås som oralt pulver til patienter, der ikke er i stand til at synke kapsler (se produktresumé for REYATAZ oralt pulver).
REYATAZ oral powder is available for patients who are unable to swallow capsules (see Summary of Product Characteristics for REYATAZ oral powder).
4. 2 og 4. 4).
Patients with moderate to severe hepatic insufficiency (see sections 4.2 and 4.4).
4. 5).
Combination of rifampicin and REYATAZ with concomitant low-dose ritonavir is contraindicated (see section 4.5).
4. 5).
REYATAZ with ritonavir must not be used in combination with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e. g., astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
4. 5).
John’ s wort (Hypericum perforatum) (see section 4.5).
Patienterne bør informeres om, at det ikke er påvist at aktuel antiretroviral behandling forhindrer overførsel af HIV til andre gennem blod eller seksuel kontakt.
Patients should be advised that current antiretroviral therapy has not been proven to prevent the risk of transmission of HIV to others through blood or sexual contact.
Der bør fortsat tages passende forholdsregler.
Appropriate precautions should continue to be employed.
Samtidig administration af REYATAZ og ritonavir i doser over 100 mg én gang dagligt er ikke evalueret klinisk.
Co-administration of REYATAZ with ritonavir in doses greater than 100 mg once daily has not been clinically evaluated.
Brug af højere doser ritonavir kan ændre sikkerhedsprofilen for atazanavir (kardielle virkninger, hyperbilirubinæmi), og kan derfor ikke anbefales.
The use of higher ritonavir doses might alter the safety profile of atazanavir (cardiac effects, hyperbilirubinaemia) and therefore is not recommended.
4. 2 og 4. 3).
Patients with coexisting conditions Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 4.3).
4. 8).
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products (see section 4.8).
Der er i kliniske undersøgelser observeret dosisrelaterede, asymptomatiske forlængelser i PR - intervallet med REYATAZ.
Dose related asymptomatic prolongations in PR interval with REYATAZ have been observed in clinical studies.
Der bør udvises forsigtighed ved lægemidler, der vides at inducere PR - forlængelser.
Caution should be used with medicinal products known to induce PR prolongations.
REYATAZ bør anvendes med forsigtighed til patienter med allerede eksisterende overledningsproblemer (andengrads - eller højere atrioventrikulær eller kompleks knude- grenblok), og kun såfremt fordelene opvejer risikoen (se pkt.
In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), REYATAZ should be used with caution and only if the benefits exceed the risk (see section 5.1).
4. 8 og 5. 3).
Particular caution should be used when prescribing REYATAZ in association with medicinal products which have the potential to increase the QT interval and/ or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Der har været rapporter om øget blødning, inklusive spontane hudhæmatomer og hæmarthrose, hos type A og B hæmofile patienter, der havde fået behandling med proteasehæmmere.
3 There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors.
3 fortsattes behandlingen med proteasehæmmere, eller behandlingen blev genoptaget hvis afbrudt.
In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued.
Omfordeling af fedt og metaboliske forstyrrelser Kombinationsbehandling med antiretrovirale midler er forbundet med omfordeling af legemsfedt (lipodystrofi) hos HIV- patienter.
Fat redistribution and metabolic disorders Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
De langsigtede konsekvenser ved disse hændelser er for øjeblikket ukendte.
The long-term consequences of these events are currently unknown.
Kendskabet til mekanismen er ufuldstændig.
Knowledge about the mechanism is incomplete.
En forbindelse mellem visceral lipomatose og proteasehæmmere og lipoatrofi og nukleosidrevers- transkriptasehæmmere er fremsat som hypotese.
A connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.
Øget risiko for lipodystrofi er forbundet med individuelle faktorer, så som alderdom, og lægemiddelrelaterede faktorer som længere varighed af antiretroviral behandling og metaboliske forstyrrelser forbundet hermed.
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
En objektiv undersøgelse bør omfatte evaluering af fysiske tegn på omfordeling af fedt.
Clinical examination should include evaluation for physical signs of fat redistribution.
Antiretroviral kombinationsbehandling (CART), også REYATAZ- baseret kombinationsbehandling (med eller uden ritonavir), er forbundet med dyslipidæmi.
Combination antiretroviral therapy (CART), including REYATAZ (with or without ritonavir)-based CART, is associated with dyslipidaemia.
Man bør overveje at måle fastende serum - lipider og blodglukose.
Consideration should be given to the measurement of fasting serum lipids and blood glucose.
REYATAZ har i kliniske undersøgelser (med eller uden ritonavir) vist sig at inducere dyslipidæmi i mindre udstrækning end andre sammenlignelige produkter, der indgik i undersøgelserne.
In clinical studies, REYATAZ (with or without ritonavir) has been shown to induce dyslipidaemia to a lesser extent than comparators.
Den kliniske betydning af fundene er ikke afklaret, da der ikke er udført specifikke undersøgelser af kardiovaskulær risiko.
The clinical impact of such findings has not been demonstrated in the absence of specific studies on cardiovascular risk.
Valg af den antiretrovirale behandling bør styres af den antivirale virkning.
The selection of antiretroviral therapy must be guided principally by antiviral efficacy.
Det anbefales at følge de gængse vejledninger ved behandling af dyslipidæmi.
Consultation with standard guidelines for management of dyslipidaemia is recommended.
Hyperglykæmi Der er rapporteret nyopstået diabetes mellitus, hyperglykæmi og forværring af eksisterende diabetes mellitus hos patienter i behandling med proteasehæmmere.
Hyperglycaemia New onset diabetes mellitus, hyperglycaemia, and exacerbation of existing diabetes mellitus have been reported in patients receiving protease inhibitors.
Hos nogle af disse var hyperglykæmien svær og i nogle tilfælde også forbundet med ketoacidose.
In some of these, the hyperglycaemia was severe and in some cases also associated with ketoacidosis.
Mange patienter havde samtidige medicinske tilstande, hvoraf nogle krævede behandling med lægemidler, som forbindes med udvikling af diabetes eller hyperglykæmi.
Many patients had confounding medical conditions, some of which required therapy with medicinal products that have been associated with development of diabetes or hyperglycaemia.
4. 8).
Hyperbilirubinaemia Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving REYATAZ (see section 4.8).
Patienter i behandling med REYATAZ, som har forhøjede levertransaminaser og forhøjet bilirubin samtidig, bør evalueres for alternative ætiologier.
Hepatic transaminase elevations that occur with elevated bilirubin in patients receiving REYATAZ should be evaluated for alternative etiologies.
4. 5).
Combinations of REYATAZ and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5).
4. 8).
Nephrolithiasis Nephrolithiasis has been reported in patients receiving REYATAZ (see section 4.8).
Hvis der opstår tegn eller symptomer på nephrolithiasis, kan midlertidig afbrydelse eller seponering af behandlingen overvejes.
If signs or symptoms of nephrolithiasis occur, temporary interruption or discontinuation of treatment may be considered.
Immunreaktiveringssyndrom Hos HIV- inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af antiretroviral kombinationsbehandling (CART) opstå inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomer.
Immune reactivation syndrome In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/ eller fokale mycobakterielle infektioner og pneumocystis carinii pneumoni.
4 Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Ætiologien anses dog for at være multifaktoriel (omfattende anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højt BMI (Body Mass Index)).
Osteonecrosis Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/ or long-term exposure to combination antiretroviral therapy (CART).
4. 5).
Interactions with other medicinal products Co-administration of REYATAZ with simvastatin or lovastatin is not recommended (see section 4.5).
4. 5).
Co-administration of REYATAZ with nevirapine or efavirenz is not recommended (see section 4.5).
Ved behov for samtidig administration af REYATAZ og en NNRTI, kan det overvejes at øge dosis af REYATAZ og ritonavir til henholdsvis 400 mg og 200 mg, i kombination med efavirenz, og under omhyggelig klinisk monitorering.
If the coadministration of REYATAZ with an NNRTI is required, an increase in the dose of both REYATAZ and ritonavir to 400 mg and 200 mg, respectively, in combination with efavirenz could be considered with close clinical monitoring.
4. 3 og 4. 5).
Co-administration of REYATAZ with ritonavir and medicinal products that induce CYP3A4 is not recommended (see sections 4.3 and 4.5).
4. 5).
The concomitant use of REYATAZ and oral contraceptives should be avoided (see section 4.5).
4. 5).
Co-administration of voriconazole and REYATAZ with ritonavir is not recommended unless an assessment of the benefit/ risk justifies the use of voriconazole (see section 4.5).
4. 5).
Concomitant use of REYATAZ/ ritonavir and fluticasone or other glucocorticoids that are metabolized by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5).
Absorptionen af atazanavir kan reduceres ved øget pH- værdi i maven, uanset årsagen til dette.
The absorption of atazanavir may be reduced in situations where gastric pH is increased irrespective of cause.
4. 5).
Co-administration of REYATAZ with proton pump inhibitors is not recommended (see section 4.5).
Dosis af protonpumpehæmmere bør ikke overstige dosis svarende til omeprazol 20 mg.
If the combination of REYATAZ with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of REYATAZ to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded.
Laktose Patienter med sjældne, arvelige problemer med galaktosetolerance, Lapp laktasemangel eller glukose - galaktose malabsorption bør ikke tage dette lægemiddel.
Lactose Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Ved samtidig administration af REYATAZ og ritonavir kan ritonavirs metaboliske lægemiddelinteraktionsprofil dominere, idet ritonavir er en mere potent CYP3A4- hæmmer end atazanavir.
When REYATAZ and ritonavir are co-administered, the metabolic drug interaction profile for ritonavir may predominate because ritonavir is a more potent CYP3A4 inhibitor than atazanavir.
Produktresumé for ritonavir bør checkes inden behandling med REYATAZ og ritonavir initieres.
The Summary of Product Characteristics for ritonavir must be consulted before initiation of therapy with REYATAZ and ritonavir.
4. 3).
Therefore, REYATAZ with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3).
Andre interaktioner Interaktioner mellem atazanavir/ ritonavir og proteasehæmmere, andre antiretrovirale midler end proteasehæmmere og andre ikke- antiretrovirale lægemidler angives i tabellerne neden for (stigninger er angivet med “ ↑ ”, fald med “ ↓ ”, ingen ændring med “ ↔ ”, to gange dagligt som “ BID ” og én gang dagligt som “ QD ”).
5 Other interactions Interactions between atazanavir/ ritonavir and protease inhibitors, antiretroviral agents other than protease inhibitors, and other non-antiretroviral medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “ BID” and once daily as “ QD”).
Undersøgelserne, der refereres til i Tabel 1, er udført med raske frivillige med mindre andet er angivet.
The studies presented in Table 1 were conducted in healthy subjects unless otherwise noted.
5 Det er vigtigt at nævne, at mange undersøgelser er udført med ikke- boosted atazanavir, hvilket ikke er det godkendte atazanavir- regime.
Of importance, many studies were conducted with unboosted atazanavir, which is not the approved regimen of atazanavir.
Interaktioner mellem REYATAZ og andre lægemidler
Interactions between REYATAZ and other medicinal products
Samtidigt administrerede
Co-administered medicinal
lægemidler (dosis i mg)
products (dose in mg)
lægemiddel
product assessed
(90% KI) (90% KI) (90% KI)
(90% CI) (90% CI) (90% CI)
vedrørende samtidig administration
co-administration
ANTI- INFEKTIONSMIDLER Antiretrovirale midler Proteasehæmmere:
ANTI-INFECTIVES Antiretrovirals Protease inhibitors:
Samtidig administration af REYATAZ/ ritonavir og andre proteasehæmmere er ikke undersøgt, men forventes at øge optagelsen af den anden proteasehæmmer.
The co-administration of REYATAZ/ ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors.
Sådan samtidig administration frarådes derfor.
Therefore, such co-administration is not recommended.
Ritonavir 100 mg QD
Ritonavir 100 mg QD
Ritonavir 100 mg QD
Ritonavir 100 mg once
(atazanavir 300 mg QD).
(atazanavir 300 mg QD)
anvendes som booster
daily is used as a
Undersøgelser udført med HIV- inficerede patienter
studies conducted in HIV- infected patients
(2, 44; 5, 03)
(2.44, 5.03)
(1, 56; 3, 11)
(1.56, 3.11)
(4, 59; 14, 39)
(4.59, 14.39)
for atazanavirs farmakokinetik.
booster of atazanavir pharmacokinetics.
* Atazanavir 300 mg og ritonavir 100 mg er i en kombineret analyse (n=33) sammenlignet med atazanavir 400 mg uden ritonavir (n=28).
* In a combined analysis, atazanavir 300 mg and ritonavir 100 mg (n=33) was compared to atazanavir 400 mg without ritonavir (n=28).
Interaktionsmekanismen mellem atazanavir og ritonavir er CYP3A4 - hæmning.
The mechanism of interaction between atazanavir and ritonavir is CYP3A4 inhibition.
Indinavir er forbundet med indirekte ukonjugeret hyperbilirubinæmi på grund af UGT- hæmning.
Indinavir is associated with indirect unconjugated hyperbilirubinaemia due to inhibition of UGT.
4. 4).
Coadministration of REYATAZ/ ritonavir and indinavir is not recommended (see section 4.4).
Nukleosid/ nukleotid reverstranskriptasehæmmere (NRTI' er) Lamivudin 150 mg BID +
Nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine 150 mg BID +
På baggrund af disse
Based on these data
zidovudin 300 mg BID (atazanavir 400 mg QD)
zidovudine 300 mg BID (atazanavir 400 mg QD)
data, og fordi ritonavir ikke forventes at have betydelig effekt på NRTI' ernes farmakokinetik, forventes samtidig administration af REYATAZ / ritonavir og disse lægemidler ikke at påvirke optagelsen af lægemidlerne i betydelig grad.
and because ritonavir is not expected to have a significant impact on the pharmacokinetics of NRTIs, the co-administration of REYATAZ/ ritonavir with these medicinal products is not expected to significantly alter the exposure of the co- administered drugs.
Samtidig administration af REYATAZ/ ritonavir og abacavir forventes ikke at påvirke optagelsen af abacavir i betydelig grad.
The co-administration of REYATAZ/ ritonavir with abacavir is not expected to significantly alter the exposure of abacavir.
Didanosin (tabletter med buffer) 200 mg/ stavudin 40 mg, begge som enkeltdoser
Didanosine (buffered tablets) 200 mg/ stavudine 40 mg, both single dose (atazanavir 400 mg
Didanosin skal tages i fastende tilstand, 2 timer efter indtag af
Didanosine should be taken at the fasted state 2 hours after
(atazanavir 400 mg som enkeltdosis)
single dose)
atazanavir, samtidig ↓0, 13 ↓0, 11 ↓0, 16 administration
atazanavir, simultaneous ↓ 0.13 ↓ 0.11 ↓ 0.16 administration
REYATAZ / ritonavir, der tages med et måltid.
The co-administration of
(0, 08; 0, 21) (0, 06; 0, 18) (0, 10; 0, 27) med ddI+d4T
(0.08, 0.21) (0.06, 0.18) (0.10, 0.27) with ddI+d4T
Samtidig
REYATAZ/ ritonavir
administration af REYATAZ /
with stavudine is not expected to
atazanavir, doseret 1 time efter ↔1, 03 ↑1, 12 ↔1, 03 ddI+d4T (0, 64; 1, 67) (0, 67; 1, 18) (0, 61; 1, 73) (fastende) Atazanavir- koncentrationen faldt meget ved samtidig administration med didanosin (tabletter med buffer) og stavudin.
atazanavir, dosed ↔ 1.03 ↑ 1.12 ↔ 1.03 1 hr after ddI+d4T (0.64, 1.67) (0.67, 1.18) (0.61, 1.73) (fasted) Atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine.
Interaktionsmekanismen er nedsat opløselighed af atazanavir på grund af en stigning i pH, der skyldes det syrehæmmende middel i didanosintabletterne med buffer.
The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets.
Der er ikke set betydelig påvirkning af didanosin - og stavudinkoncentrationer.
No significant effect on didanosine and stavudine concentrations was observed.
ritonavir og stavudin forventes ikke at påvirke optagelsen af stavudin i betydelig grad.
significantly alter the exposure of stavudine.
Samtidigt administrerede lægemidler (dosis i mg)
Co-administered medicinal products (dose in mg)
Vurderet AUC Cmax Cmin lægemiddel (90% KI) (90% KI) (90% KI)
Medicinal AUC Cmax Cmin product assessed (90% CI) (90% CI) (90% CI)
Tenofovir- disoproxilfumarat
Didanosine (enteric coated
atazanavir
Didanosine (with
↓0, 78 *
↓ 0.66
↓0, 84 *
↓ 0.62
↓0, 77 *
↑ 1.25
300 mg QD (atazanavir 300
capsules) 400 mg single dose (atazanavir 300 mg QD with
(0, 65; 0, 94)
(0.59, 0.73)
(0, 70; 1, 00)
(0.52, 0.74)
(0, 57- 1, 02)
(0.92, 1.69)
mg QD med ritonavir 100 mg QD).
ritonavir 100 mg QD)
Undersøgelser udført med HIV- inficerede patienter.
300 mg QD (atazanavir 300 mg QD with ritonavir 100 mg QD) studies conducted in HIV- infected patients
* I en kombineret analyse af flere kliniske undersøgelser, hvor atazanavir/ ritonavir 300/ 100 mg administreret samtidig med tenofovir - disoproxilfumarat 300 mg (n=39) blev sammenlignet med atazanavir/ ritonavir 300/ 100 mg (n=33).
(0.65, 0.94) (0.70, 1.00) (0.57-1.02) * In a combined analysis from several clinical studies, atazanavir/ ritonavir 300/ 100 mg co-administered with tenofovir disoproxil fumarate 300 mg (n=39) was compared to atazanavir/ ritonavir 300/ 100 mg (n=33).
4. 8 og 5. 1).
The efficacy of REYATAZ/ ritonavir in combination with tenofovir in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Interaktionsmekanismen mellem atazanavir og tenofovir er ukendt.
The mechanism of interaction between atazanavir and tenofovir is unknown.
300 mg QD (atazanavir 300
Tenofovir disoproxil fumarate 300 mg QD (atazanavir 300
tenofovir - ↑1, 37 ↑1, 34 ↑1, 29
tenofovir
monitoreres tæt for
Patients should be closely monitored for
mg QD med ritonavir 100 mg
mg QD with ritonavir 100 mg
disoproxil - (1, 30; 1, 45) (1, 20; 1, 51) (1, 21; 1, 36)
↑ 1.37 ↑ 1.34 ↑ 1.29 disoproxil
tenofovir- relaterede
tenofovir-associated
QD)
QD)
fumarat
(1.30, 1.45) (1.20, 1.51) (1.21, 1.36) fumarate
bivirkninger, inklusive nyrelidelser.
adverse events, including renal disorders.
Non- nukleosid reverstranskriptasehæmmere (NNRTI' er) Efavirenz 600 mg QD
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg QD
atazanavir (aften):
atazanavir (pm):
Samtidig
Co-administration of
(atazanavir 400 mg QD med
(atazanavir 400 mg QD with
alle administreret
all administered
administration af
efavirenz with
ritonavir 100 mg QD)
ritonavir 100 mg QD)
med mad
with food
(0, 91; 1, 10)
(0.91, 1.10)
(1, 08; 1, 27)
(1.08, 1.27)
(0, 49; 0, 69)
(0.49, 0.69)
efavirenz og REYATAZ /
REYATAZ/ ritonavir is not recommended (see